SCHEMBL4724745

SCHEMBL4724745

COCc1nnc(NC2CCN(Cc3ccc(OC4CCCN(C)CC4)cc3)CC2)c2cc(OC)ccc12

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DNMT3A Q9Y6K1 2/20 0.44
HRH3 Q9Y5N1 2/20 0.44
EHMT1 Q9H9B1 4/20 0.44
MCHR1 Q99705 5/20 0.43
EHMT2 Q96KQ7 7/20 0.43
KDM1A O60341 2/20 0.43
RCOR1 Q9UKL0 1/20 0.43
NSD2 O96028 3/20 0.42
NSD3 Q9BZ95 3/20 0.42
NPC1 O15118 1/20 0.42
MTOR P42345 1/20 0.42
RAB9A P51151 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
EZH2 Q15910 2/20 0.41
KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4124308 0.99 DNMT3A (0.43) DNMT3AHRH3EHMT1MCHR1EHMT2
SCHEMBL4763144 0.90 DNMT3A (0.46) DNMT3AHRH3EHMT1MCHR1EHMT2
Hydrochloric Acid SCHEMBL4118824 0.89 DNMT3A (0.45) DNMT3AHRH3EHMT1MCHR1EHMT2
SCHEMBL4723726 0.87 ACHE (0.47) DNMT3AHRH3EHMT1MCHR1EHMT2
Hydrochloric Acid SCHEMBL4129881 0.87 ACHE (0.47) DNMT3AHRH3EHMT1MCHR1EHMT2
SCHEMBL4130305 0.86 DNMT3A (0.44) DNMT3AEHMT1MCHR1EHMT2KDM1A
Hydrochloric Acid SCHEMBL4125642 0.86 DNMT3A (0.44) DNMT3AEHMT1MCHR1EHMT2KDM1A
SCHEMBL13850602 0.84 DNMT3A (0.49) DNMT3AEHMT1MCHR1EHMT2NSD2
SCHEMBL4764537 0.84 DNMT3A (0.45) DNMT3AEHMT1MCHR1EHMT2KDM1A
SCHEMBL4116963 0.84 DNMT3A (0.60) DNMT3AEHMT1MCHR1EHMT2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940823-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 EP claimed
WO-2007042660-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-04-19 WO claimed
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-05-14 US disclosed
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2009-05-14 US disclosed
EP-1940823-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 EP disclosed
WO-2007042660-A2 SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124624-A1 SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AGTR1, AGTR2, AHR DNMT3A 3277/4885HRH3 165/4885EHMT1 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.